Manzo Pharmaceuticals, Inc. (MNZO)
Manzo Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Milford, PA, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $115,952. On trailing twelve-month figures it carries a trailing P/E of -9.83, a net margin of 0.0%. Its beta of -0.60 implies it has historically moved less than the broad market.
Manzo Pharmaceuticals, Inc. is a specialized drug company that focuses on the discovery, creation, and evaluation of both proprietary and generic medical treatments and therapies. The company is actively developing Lacto-Freedom, a patented probiotic designed to help individuals with lactose intolerance digest dairy-containing foods more easily. Additionally, it is crafting a natural solution for infant colic. Headquartered in Milford, Pennsylvania, the organization was formerly known as Fortune Oil & Gas, Inc. before adopting its current name, Manzo Pharmaceuticals, Inc., in September 2014.
Manzo Pharmaceuticals, Inc. is most often compared with the following Healthcare names: